This study concluded that SGLT2 inhibitors significantly reduced incidents of cardiovascular death and heart failure among cohorts with chronic kidney disease, heart failure, and type 2 diabetes mellitus [31]. This evidence concerns the gene SLC5A2 and chronic kidney disease.